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Abstract: Response classification after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma
is based on the TNM stage at radical cystectomy. We recently showed that histopathologic tumor
regression grades (TRGs) add prognostic information to TNM. Our aim was to validate the prognostic
significance of TRG in muscle-invasive bladder cancer in a multicenter setting. We enrolled 389 patients
who underwent cisplatin-based chemotherapy before radical cystectomy in 8 centers between 2010 and
2016. Median follow-up was 2.2 years. TRG was determined in radical cystectomy specimens by local
pathologists. Central pathology review was conducted in 20% of cases, which were randomly selected.
The major response was defined as ฀pT1N0. The remaining patients were grouped into partial responders
(฀ypT2N0-3 and TRG 2) and nonresponders (฀ypT2N0-3 and TRG 3). TRG was successfully determined
in all cases, and interobserver agreement in central pathology review was high (฀=0.83). After combining
TRG and TNM, 47%, 15%, and 38% of patients were major, partial, and nonresponders, respectively.
Combination of TRG and TNM showed significant prognostic discrimination of overall survival (major
responder: reference; partial responder: hazard ratio 3.5 [95% confidence interval: 1.8-6.8]; nonresponder:
hazard ratio 6.1 [95% confidence interval: 3.6-10.3]). This discrimination was superior compared with
TNM staging alone, supported by 2 goodness-of-fit criteria (P=0.041). TRG is a simple, reproducible
histopathologic measurement of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Integrating TRG with TNM staging resulted in significantly better prognostic stratification than TNM
staging alone.
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Abstract: Response classification after neoadjuvant chemotherapy
in muscle-invasive bladder carcinoma is based on the TNM stage at
radical cystectomy. We recently showed that histopathologic tumor
regression grades (TRGs) add prognostic information to TNM.
Our aim was to validate the prognostic significance of TRG in
muscle-invasive bladder cancer in a multicenter setting. We enrolled
389 patients who underwent cisplatin-based chemotherapy before
radical cystectomy in 8 centers between 2010 and 2016. Median
follow-up was 2.2 years. TRG was determined in radical cys-
tectomy specimens by local pathologists. Central pathology review
was conducted in 20% of cases, which were randomly selected. The
major response was defined as ≤pT1N0. The remaining patients
were grouped into partial responders (≥ypT2N0-3 and TRG 2)
and nonresponders (≥ypT2N0-3 and TRG 3). TRG was success-
fully determined in all cases, and interobserver agreement in central
pathology review was high (κ= 0.83). After combining TRG and
TNM, 47%, 15%, and 38% of patients were major, partial, and
nonresponders, respectively. Combination of TRG and TNM
showed significant prognostic discrimination of overall survival
(major responder: reference; partial responder: hazard ratio 3.5
[95% confidence interval: 1.8-6.8]; nonresponder: hazard ratio 6.1
[95% confidence interval: 3.6-10.3]). This discrimination was supe-
rior compared with TNM staging alone, supported by 2 goodness-
of-fit criteria (P= 0.041). TRG is a simple, reproducible histo-
pathologic measurement of response to neoadjuvant chemotherapy
in muscle-invasive bladder cancer. Integrating TRG with TNM
staging resulted in significantly better prognostic stratification than
TNM staging alone.
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Neoadjuvant chemotherapy followed by radical cystectomyis the gold-standard treatment for patients with muscle-
invasive bladder carcinoma.1 However, up to 60% of patients
treated with neoadjuvant chemotherapy have residual muscle-
invasive bladder cancer at radical cystectomy.2 These patients
have a significantly worse overall survival (OS) compared with
patients achieving a pathologic complete response after neo-
adjuvant chemotherapy.3,4
As patients who do not respond to neoadjuvant
chemotherapy have no obvious benefit from therapy but
suffer potential toxicity of therapy and delay in definitive
surgery, it stands to reason that the ability to select patients for
neoadjuvant chemotherapy based on the likelihood of response
would improve patient outcomes. Therefore, research has
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focused on discovery and validation of predictive biomarkers.
However, previous studies investigating predictive biomarkers
have used different TNM categories to define response to ne-
oadjuvant chemotherapy.5–7 This variability may indicate the
need for a more granular definition of response, determined in
bladder carcinoma treated with neoadjuvant chemotherapy.
Furthermore, while it is presumed that patients with residual
muscle-invasive bladder cancer after neoadjuvant chemo-
therapy have derived no benefit from neoadjuvant chemo-
therapy, this has not been definitively demonstrated.
Histopathologic tumor regression grades (TRGs),
which quantify the extent of tumor response to systemic
treatment, have shown to be a prognostic factor for patient
outcome in several malignancies, including gastric, esoph-
ageal, and rectal carcinoma.8–10 In muscle-invasive bladder
cancer, Fleischmann et al11 found that TRG predicted
survival after neoadjuvant chemotherapy independently
and better than conventional pathologic TNM response
classification. The aim of the present study was to inves-
tigate whether the prognostic significance of TRG could be
validated in a multicenter cohort of muscle-invasive bladder
cancer patients who underwent neoadjuvant chemotherapy
followed by radical cystectomy.
MATERIALS AND METHODS
Patient Population
We enrolled a consecutive cohort of patients who
underwent neoadjuvant chemotherapy followed by radical
cystectomy for cT2-4aN0-3M0 bladder carcinoma between
2010 and 2016 in 8 institutions. Although systemic chemo-
therapy for cN1-3 bladder carcinoma is conventionally referred
to as induction chemotherapy, we included it here under the
term neoadjuvant chemotherapy. Data were collected in
accordance with institutional and national ethical guidelines.
Only patients who underwent 3 or 4 cycles of cisplatin-based
neoadjuvant chemotherapy were included. Exclusion criteria
were a history of pelvic radiotherapy and nonurothelial pri-
mary histology. Urothelial carcinoma with squamous and/or
glandular differentiation was allowed (Fig. 1). Follow-up was
performed according to institutional protocols. Generally,
patients were evaluated every 3 to 4 months for the first
year after radical cystectomy, semiannually for the second
year, and annually thereafter.
Pathology
Each center processed the radical cystectomy speci-
mens according to its own institutional protocols. In
general, protocols for fixation and pathologic examination
were similar between pathology departments. Radical
cystectomy specimens were fixed in 10% neutral buffered
formalin (4% formaldehyde) for 24 to 48 hours at room
temperature. Characteristics of bladder lesions (residual
tumors, ulcers, scars) were described (location, relation to
the bladder wall and surrounding tissues), and corre-
sponding tissue samples were taken for histologic exami-
nation. Generally, samples from the bladder neck with
trigone, dome, and anterior and posterior wall, and the
resection margins of ureters and urethra were embedded.
Microscopically, tumor grade and tumor stage were not-
ed. Lymph node (LN) specimens were examined by in-
spection and palpation, and all macroscopically detected
LNs were embedded completely. For this study, all hem-
atoxylin & eosin–stained sections from all patients were
re-evaluated by uropathologists (H.Z.O., V.G., L.A.S., J.F.,
J.F.C., M.M., M.C., and L.B.) in each center. Scoring of
regression is described in detail in the next paragraph.
A random selection of 20% of cases from each center
was reviewed independently by 2 pathologists: the institution’s
local uropathologist and a central pathology reviewer (V.G.).
One center (INT Milan) could not participate in central
pathology review (CPR) due to logistical constraints. All
pathologists were blinded from clinical information, treatment
regimens, and study endpoints. In addition, the central
pathology reviewer was blinded from other pathologists’ in-
terpretations. Major pathologic response to neoadjuvant
chemotherapy according to conventional TNM staging was
defined as ≤ypT1N0. Nonmajor pathologic response was
defined as ypT2-4Nany or ypTanyN1-3.
Classification of TRG
TRG was based on an estimation of the percentage
of viable cancer cells in relation to the macroscopically
identifiable tumor bed, indicated by zones of fibrosis in the
bladder wall and in the perivesical soft tissue, as pre-
viously described.11 The following 3 TRGs were dis-
tinguished (Fig. 2A, Supplemental Fig. 1, Supplemental
Digital Content 1, http://links.lww.com/PAS/A840):
TRG 1:Complete response: the absence of histo-
logically identifiable residual cancer cells
and extensive fibrosis of the tumor bed.
TRG 2: Strong response: predominant fibrosis of the
tumor bed with residual cancer cells occu-
pying <50% of this area.
TRG 3: Weak and no response: residual cancer cells
occupying ≥ 50% of the tumor bed or ab-
sence of regressive changes.
This grading system was used separately for primary
tumors and LN metastases (Figs. 3, 4). For every patient,
FIGURE 1. Flowchart of patient selection. MIBC indicates muscle-
invasive bladder cancer; NAC, neoadjuvant chemotherapy.
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the dominant TRG, defined as the higher TRG between
primary tumor and LNs, was used as the final grade.
Response to neoadjuvant chemotherapy was classified into
3 categories on the basis of a combination of TNM stage
and TRG: major response, partial response, and no response














FIGURE 2. A, Representative hematoxylin and eosin images of TRG 1 (uppermost) with inflammatory infiltrate (arrows), TRG 2 (middle), and
TRG 3 (lowermost) with muscle-invasive bladder cancer cells, within the original tumor bed. The dashed line delimits cancer cells. The
respective zoomed images from the insets (left panel) are shown on the right. Scale bar represents 100 µm. B, Schematic description of the
combination of TRG and TNM stage, showing how TRG stratifies partial and nonresponders on the basis of the histopathologic response.
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muscle-invasive disease and LN involvement (≤ypT1N0).
Partial response was defined as ≥ypT2N0-3 with TRG 2.
Finally, patients with ≥ypT2N0-3 and TRG 3 were consi-
dered to have no response to neoadjuvant chemotherapy.
Statistical Analysis
Statistical analyses were performed using IBM SPSS
Statistics, version 22.0 (IBM Corp., Armonk, NY) and R
version 3.4.4 (R Foundation for Statistical Computing,
Vienna, Austria). All tests were 2 sided, with the level of
significance set at P-value <0.05. The 3 TRGs were
compared with clinicopathologic characteristics using
analysis of variance for continuous data and the Pearson
χ
2 test for categorical data. Kaplan-Meier plots were used
to estimate OS from the time of radical cystectomy to the
date of death. Comparisons between response groups were
made using the log-rank test. Patients still alive were
censored at the date of the last follow-up. Median follow-
up was calculated using the reverse Kaplan-Meier method.
The level of agreement between TRG score by the
local pathologist and the central pathology reviewer was
expressed by means of a Cohen κ coefficient. In case of
discrepancy between the local pathologist and the central
pathology reviewer, the TRG determination of the former
was used for further analysis.
The association between pathologic response and OS
was assessed using Cox proportional hazard models. To
compare response according to the conventional patho-
logic stage and according to staging including TRG, 2
models were created. Model 1 included age, sex, surgical
margin status, and conventional pathologic response as
covariates, whereas model 2 included a combination of
TNM stage and TRG. Model fit was compared using the
likelihood ratio test and the Akaike Information Criterion
(AIC). The AIC adjusts the −2 log-likelihood statistic for
the number of parameters in the model and number of
observations used. A smaller AIC indicates a more desir-
able model for predicting the outcome.
Sample Size Calculation
The minimum size of the study cohort was determined
by a power analysis based on observed outcomes in the pre-
vious study on TRG in muscle-invasive bladder cancer.11 The
anticipated event rate was 35%. Assuming a Cox regression
coefficient of 1.8 and an SD of 0.4, ∼44 nonresponders were
needed to achieve 80% power at a 0.05 significance level. In
addition, ∼26 partial responders were needed (20% partial
responders in previous data sets). With use of these variables,
a total of at least 130 patients was required.
RESULTS
Patient and Tumor Characteristics
Radical cystectomy specimens of 389 patients were
evaluated. Clinicopathologic characteristics stratified by TRG
are shown in Table 1. Lower TRG was associated with lower
ypT categories (P<0.001) and with the absence of LN
metastases (P<0.001). There was also a significant association
between variant histology (ie, urothelial carcinoma with either
squamous differentiation (n=34) or glandular differentiation
(n=4)) and higher TRG, with more patients having variant










FIGURE 3. Representative hematoxylin and eosin images in a partially regressed LN metastasis with a scanty piece of viable cancer cells,
TRG 2. The respective zoomed images (i, ii, iii) of the insets from the original tumor bed (top left, low power view) are shown. (i) Remaining
bladder cancer cells in the displaced LN structure. Higher magnification shows dense fibrosis and a nodular accumulation of foamy
macrophages (arrowheads) (ii) and nodular zone of necrosis, surrounded by granulation tissue and remaining LN (iii).
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FIGURE 4. Representative hematoxylin and eosin images of LN TRG 1 (uppermost) with fibrotic tumor bed and remaining LN. LN
TRG 2 (middle) with necrosis and a small island of residual cancer cells (arrows). LN TRG 3 (lowermost) with cancer cells displacing
almost the entire LN and arrowheads show the remaining LN. The respective zoomed images from the insets (left panel) are shown
on the right. Scale bar represents 100 μm.
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Pathologic Response
At the time of radical cystectomy, 139/389 (36%) patients
had no residual primary tumor (ypT0) and 305/389 (78%)
patients had no LN metastases (ypN0). Seven patients had no
residual primary tumor but were LN positive (ypT0N+). Ac-
cording to the conventional TNM response definition, 181/389
patients (47%) had a major response, whereas 208/389 (53%)
were nonmajor responders. TRG was successfully determined
in all cases. For every patient, the corresponding TRG in the
primary tumors and in the LNs is given in Table 2. When
combining TRG with the TNM stages, 181 (47%), 59 (15%),
and 149 (38%) patients were major, partial, and nonresponders,
respectively.
Central Pathology Review
Local pathologists and the central pathology reviewer
agreed on TRG in 88% (46/52) of cases. The overall kappa
between the central pathology reviewer and local patholo-
gists was 0.82.
Survival
During a median follow-up of 2.2 years (95% confidence
interval [CI]: 2.0-2.4), 112/389 patients had a cancer recurrence,
and 98/389 patients died. In the TRG 1 group, median OS
was not reached, whereas, in the TRG 2 and TRG 3 groups,
median OS was 3.3 (95% CI: 2.4-4.1) and 2.6 years (95% CI:
1.6-3.6), respectively (P=0.026). As expected, higher ypT
and higher ypN stage were significantly associated with worse
OS in Kaplan-Meier analysis (P<0.001, Figs. 5A, B). Positive
TABLE 1. Patient and Tumor Characteristics by TRG
TRG, n (%)
Total, n (%) 1 2 3 P
Total number of patients 389 (100) 132 (33.9) 107 (27.5) 150 (38.6) —
Age, median (IQR) (y) 63 (55-69) 63 (55-70) 63 (55-68) 63 (55-68) 0.8
Sex
Male 282 (72.5) 109 (71.2) 69 (80.2) 104 (69.3) 0.2
Female 107 (27.5) 44 (28.8) 17 (19.8) 46 (30.7)
cT stage
cT2 196 (50.4) 93 (60.8) 38 (44.2) 65 (43.3) 0.2
cT3 145 (37.3) 44 (28.8) 36 (41.9) 65 (43.3)
cT4a 48 (12.3) 16 (10.5) 12 (14.0) 20 (13.3)
cN stage
cN0 309 (79.4) 127 (83.0) 59 (68.6) 123 (82.0) 0.2
cN1-3 80 (20.6) 26 (17.0) 27 (31.4) 27 (18.0)
NAC regimen
GC 298 (76.6) 115 (75.2) 62 (72.1) 121 (80.7) 0.4
MVAC 91 (23.4) 38 (24.8) 24 (27.9) 29 (19.3)
No. NAC cycles
3 116 (29.8) 44 (28.8) 28 (32.6) 44 (29.3) 0.8
4 273 (70.2) 109 (71.2) 58 (67.4) 106 (70.7)
ypT stage
ypT0 139 (35.7) 132 (100) 7 (6.5) 0 (—) < 0.001
ypTa/is/1 55 (14.1) 0 (—) 53 (49.5) 2 (1.3)
ypT2 98 (25.2) 0 (—) 31 (30.0) 67 (44.7)
ypT3 72 (18.5) 0 (—) 12 (11.2) 60 (40.0)
ypT4 25 (6.4) 0 (—) 4 (3.7) 21 (14.0)
ypN stage
ypN0 305 (78.4) 153 (100) 61 (70.9) 91 (60.7) < 0.001
ypN1-3 84 (21.6) 0 (—) 25 (29.1) 59 (39.3)
Histology
Urothelial 351 (90.2) 147 (96.1) 80 (93.0) 124 (82.7) 0.002
Squamous differentiation 34 (8.7) 6 (3.9) 5 (5.8) 23 (15.2)
Glandular differentiation 4 (1.0) 0 (—) 1 (1.2) 3 (2.0)
LVI
Yes 66 (23.4) 122 (99.2) 50 (79.4) 44 (45.8) < 0.001
No 216 (76.6) 1 (0.8) 13 (20.6) 52 (54.2)
Missing 107
Surgical margin
Positive 19 (4.9) 0 (—) 2 (2.3) 17 (11.3) < 0.001
Negative 370 (95.1) 153 (100) 84 (97.7) 133 (88.7)
Bold value indicates statistically significant (P< 0.05).
GC indicates gemcitabine and cisplatin; IQR, interquartile range; LVI, lymphovascular invasion; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; NAC,
neoadjuvant chemotherapy.
TABLE 2. TRGs of Primary Tumors and LN Metastases
Primary Tumor
LN Metastases TRG 1 TRG 2 TRG 3
TRG 1 132 75 91
TRG 2 7 25 0
TRG 3 0 0 59
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surgical margin status was also significantly associated with
worse OS (P<0.001, Fig. 5C), whereas variant histology was
not (P=0.06, Fig. 5D).
Kaplan-Meier analysis showed a significant difference
in OS between major responders and nonmajor responders
on the basis of TNM staging alone (P<0.001, Fig. 6A).
Integrating TRG in the conventional TNM staging showed
further stratification of survival curves, discriminating 3
groups of patients with significantly different OS (P<0.001,
Fig. 6B). Subgroup analysis of TRG 2 versus TRG 3 within
ypT2 or ypT3/4 stages showed no significant difference in OS
(ypT2: TRG 2 [n=31] vs. TRG 3 [n=67], P=0.3; ypT3/4:
TRG 2 [n=16] vs. TRG 3 [n=81], P=0.2, Figs. 7A, B).
Subgroup analysis of TRG 2 versus TRG 3 among patients
with LN metastases (n=84) showed a significant difference
in OS (P=0.03, Fig. 7C).
In univariable analysis, a higher TRG significantly
correlated with worse survival (P< 0.001, Table 3). Other
factors associated with worse OS were higher ypT and
ypN stages and positive surgical margins (all P< 0.001). In
multivariable analysis, a combination of TRG and TNM
showed a significant association with survival (P<0.001),
discriminating 3 groups of patients with significantly different
OS (Table 4).
FIGURE 5. Kaplan-Meier plots for OS stratified according to ypT stage (A), ypN stage (B), surgical margin status (C), and histology
type (D). UCC indicates urothelial carcinoma.
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Comparison of Prognostic Models
To assess the prognostic value of the combination of
TRG and TNM in addition to the value of conventional
TNM staging, the 2 Cox proportional hazard models
(Table 4) were compared using a likelihood ratio test. Model 2
(including the combination of TRG and TNM) had a lower
test statistic than model 1 (including conventional response
classification) (489.54 vs. 491.64, P=0.041). Therefore, the
model including TRG and TNM proved to be a more
desirable model for prognostication. Moreover, the AIC value
was smaller for the combination of TRG and TNM (AIC:
967.58) compared with that for TNM staging alone (AIC:
973.14), indicating that the former has a better prognostic
stratification. Sensitivity analysis excluding patients from the
center that did not participate in CPR did not impact the
study findings (data not shown).
DISCUSSION
In this retrospective multicenter analysis, we determined
histopathologic TRGs in radical cystectomy specimens of
muscle-invasive bladder cancer patients after neoadjuvant
chemotherapy. TRGs were confirmed by independent patho-
logic review with low interobserver variability. We could not
only validate the prognostic significance of TRG but also
provided an easily applicable score, including TNM and
TRG, that serves as a prognostic posttreatment classification
system. Determination of this score in radical cystectomy
specimens after neoadjuvant chemotherapy is simple, re-
producible, and provides additional prognostic information. If
this can be confirmed in a prospective study, TRG may be
routinely added to pathology reports of radical cystectomy
specimens after neoadjuvant chemotherapy.
In contrast to other cancers,8–10 classification of re-
sponse to neoadjuvant chemotherapy in muscle-invasive
bladder cancer is only based on TNM staging at radical
cystectomy.12 However, as TNM staging is developed in
untreated muscle-invasive bladder cancer, it does not
consider specific alterations caused by neoadjuvant che-
motherapy and may, therefore, conceal prognostic in-
formation in posttreatment specimens. In addition,
variability in pathologic TNM staging is a recognized
problem in non–muscle-invasive bladder carcinoma,13 and
some studies suggest that interobserver variability may
also affect TNM staging in muscle-invasive bladder
cancer.14,15 These issues substantiate a need to improve
posttreatment stratification.
Fleischmann et al11 were the first to show that his-
tomorphologic classification of postchemotherapy cys-
tectomy specimens into TRGs harbors prognostic
information. However, this was a single-center cohort that
mainly consisted of patients with advanced muscle-in-
vasive bladder cancer (cT3/4 and/or cN+). In the current
study, we performed independent validation of the find-
ings of Fleischmann and colleagues in an evenly balanced
cohort, including cT2N0 patients. Thus, the present co-
hort represents a practice of treating “all-comers” with
neoadjuvant chemotherapy and confirms that TRG also
harbors prognostic information in a clinically lower-staged
muscle-invasive bladder cancer cohort.
Our findings may be in contrast to another study
investigating the prognostic value of TRG in muscle-invasive
bladder cancer.16 This multicenter study by Brimo and
colleagues also identified TRGs as a prognostic parameter
in univariable analyses, but this was not confirmed in multi-
variable analysis. However, there are some important differ-
ences between the study of Brimo and colleagues and our
study. First, our sample size met the requirement of the power
calculation, while the study of Brimo and colleagues may
have been underpowered (n=165). Moreover, we excluded
aggressive histomorphologic variants, in line with the large
randomized controlled trials on neoadjuvant chemotherapy in
FIGURE 6. Kaplan-Meier plots for OS stratified according to conventional TNM response classification (major responder and
nonmajor responder) (A) and TRG integrated with TNM staging (B).
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muscle-invasive bladder cancer,17,18 whereas Brimo et al16 did
not.16 Taken together, our study provided a multicenter
validation of the prognostic significance of TRG in muscle-
invasive bladder cancer after neoadjuvant chemotherapy.
Several reasons may explain why TRGs are com-
monly used in gastrointestinal malignancies and not in
muscle-invasive bladder carcinoma. Histomorphologi-
cally, the layers of the gastrointestinal wall are clearly
defined, in contrast to the layers of the bladder wall. This
may contribute to less accurate clinical staging in bladder
carcinoma and a more challenging estimation of tumor
shrinkage due to chemotherapy. Moreover, while diag-
nostic biopsy of, for example, esophageal carcinoma has
limited effect on tumor size and architecture, transurethral
resection (TUR) of the bladder tumor affects not only
tumor size but also histopathologic findings. Two studies
addressed the potential confounding effect of TUR in re-
lation to neoadjuvant chemotherapy. Wang et al19 found
that both neoadjuvant chemotherapy and TUR cause fi-
broblastic reaction and necrosis, while hyalinization of the
bladder wall is specifically seen after neoadjuvant che-
motherapy. Brant et al20 evaluated histologic changes af-
ter neoadjuvant chemotherapy in 139 patients with cT2
bladder carcinoma and estimated that 38% of pathologic
response could be attributed to TUR alone. They did not
include higher staged patients, and both did not assess
clinical outcomes. Moreover, the residual tumor size in
relation to the estimated former tumor bed was not con-
sidered, although this is an important feature of TRG
determination. Even if TUR causes regressive changes,
these will be limited to the bladder wall and will neither
affect the perivesical fat nor impact the size of the former
tumor bed. Finally, the prognostic significance of TRG in
the present more evenly balanced cohort including high-
stage muscle-invasive bladder cancer patients cannot be
negated and suggests clinical applicability.
TRG may serve as a useful tool in clinical practice
and research for several reasons. First, integrating TRG
with TNM staging resulted in more accurate survival
prediction and may be helpful in decisions with regard to
FIGURE 7. Kaplan-Meier plots for OS stratified according to TRG within ypT2 (A), ypT3/4 (B), and ypN1-3 (C).
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the timing of follow-up.21 Second, TRG could be used to tailor
therapeutic adjuvant strategies in patients with residual tumor
after neoadjuvant chemotherapy. TRG provides the oppor-
tunity to gage antitumor efficacy of agents, and persistence
of viable tumor after therapy might indicate the need to alter or
explore novel treatments in the adjuvant setting. Third, TRG
could be used as a comparative parameter for biomarker
studies. A standard approach for grading pathologic response
to neoadjuvant chemotherapy is important for the assessment
of predictive biomarkers and will facilitate comparison of
results across studies.
Our study is limited by its retrospective design, possibly
resulting in differences in grossing protocols across institutions.
Nevertheless, we performed CPR and found high interobserver
agreement. One center could not participate in CPR, but sen-
sitivity analysis restricted to centers who did participate in CPR
did not alter the main study findings. Importantly, we enrolled
a homogenous cohort of neoadjuvant chemotherapy patients,
including only common variant histologies in line with current
clinical trials, and all patients received at least 3 cycles of
cisplatin-based neoadjuvant chemotherapy.
In conclusion, this study validates TRG as an in-
dependent predictor of OS in a multicenter series of pa-
tients with muscle-invasive bladder cancer who received
cisplatin-based chemotherapy before radical cystectomy.
TRG is a simple and highly reproducible measurement of
response to neoadjuvant chemotherapy. Importantly, in-
tegrating TRG with TNM staging resulted in significantly
better prognostic stratification than conventional TNM
staging alone. Therefore, we suggest that TRG may rou-
tinely be included in postchemotherapy pathologic reports
of radical cystectomy specimens. In addition to predicting
patient outcome, combining TRG and TNM may be used
to tailor postoperative treatment and may serve as a
comparative parameter for predictive biomarkers.
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